Trial Information
A Non-interventional Multicenter Study of First-line AvastinĀ® (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
Inclusion Criteria:
- Adult patients, age >/=18 years
- Proven metastatic colorectal carcinoma
- Patients have measurable disease
- Patients are eligible to receive first-line Avastin
- Patients have signed data release form
Exclusion Criteria:
- Contra-indication to receive Avastin according to the local labeling
- Participation in a clinical study within 30 days prior to enrolment
- Patients have any other primary cancer
- Concomitant treatment with other biologics
- History of other malignant disease in the past 5 years except basal cell carcinoma
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival in a real life setting assessed by computer tomography
Outcome Time Frame:
Approximately 2 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Lebanon: Ministry of Public Health
Study ID:
ML25198
NCT ID:
NCT01266564
Start Date:
September 2010
Completion Date:
February 2014
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms